Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM.

J Clin Oncol. 2009 Sep 1;27(25):4055-61. doi: 10.1200/JCO.2008.19.5776. Epub 2009 Jul 27.

2.

Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.

Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL.

Eur Urol. 2012 Apr;61(4):705-11. doi: 10.1016/j.eururo.2011.11.010. Epub 2011 Nov 12.

PMID:
22101114
3.

Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL.

J Clin Oncol. 2014 Dec 1;32(34):3801-9. doi: 10.1200/JCO.2014.57.5548. Epub 2014 Nov 3. Erratum in: J Clin Oncol. 2015 Mar 1;33(7):814.

4.

Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.

Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL.

Lancet Oncol. 2013 Aug;14(9):863-72. doi: 10.1016/S1470-2045(13)70255-9. Epub 2013 Jul 1.

5.

Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy.

Liu M, Pickles T, Agranovich A, Berthelet E, Duncan G, Keyes M, Kwan W, McKenzie M, Morris J, Pai H, Tyldesley S, Wu J.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):59-67.

PMID:
14697421
6.

Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.

Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, Zietman AL, Tanguay S, Sandler HM.

Urology. 2009 Apr;73(4):833-7. doi: 10.1016/j.urology.2008.09.036. Epub 2008 Dec 18.

PMID:
19100600
7.

RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.

Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):665-72.

PMID:
14529770
8.

Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.

Lee CY, Yang KL, Ko HL, Huang RY, Tsai PP, Chen MT, Lin YC, Hwang TI, Juang GD, Chi KH.

Radiat Oncol. 2014 Sep 24;9:213. doi: 10.1186/1748-717X-9-213.

9.

Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.

Chen WC, Liaw CC, Chuang CK, Chen MF, Chen CS, Lin PY, Chang PL, Chu SH, Wu CT, Hong JH.

Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):726-33.

PMID:
12788178
10.

Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria.

Choo R, Pearse M, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P.

Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):989-95. doi: 10.1016/j.ijrobp.2008.02.044. Epub 2008 Apr 23.

PMID:
18436391
11.

A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.

Fang P, Mick R, Deville C, Both S, Bekelman JE, Christodouleas JP, Guzzo TJ, Tochner Z, Hahn SM, Vapiwala N.

Cancer. 2015 Apr 1;121(7):1118-27. doi: 10.1002/cncr.29148. Epub 2014 Nov 25.

12.

Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.

Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, Zelefsky MJ.

Eur Urol. 2011 Dec;60(6):1142-8. doi: 10.1016/j.eururo.2011.08.006. Epub 2011 Aug 12.

PMID:
21855208
13.

Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.

Mitin T, George A, Zietman AL, Heney NM, Kaufman DS, Uzzo RG, Dreicer R, Wallace HJ 3rd, Souhami L, Dobelbower MC, Sandler HM, Shipley WU.

Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):67-74. doi: 10.1016/j.ijrobp.2015.09.030. Epub 2015 Sep 28.

15.

Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.

Iida S, Kondo T, Kobayashi H, Hashimoto Y, Goya N, Tanabe K.

Int J Urol. 2009 Mar;16(3):287-92. doi: 10.1111/j.1442-2042.2008.02239.x. Epub 2009 Feb 4.

16.

Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.

George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.

Urology. 2004 Sep;64(3):488-93. Review.

PMID:
15351577
17.

Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.

Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, Roach M, Parliament MB, Pollack A, Markoe AM, Harms W, Sandler HM, Cox JD.

Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):192-8.

PMID:
12694838
18.

Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.

Gogna NK, Matthews JH, Turner SL, Mameghan H, Duchesne GM, Spry N, Berry MP, Keller J, Tripcony L; Trans Tasman Radiation Oncology Group.

Radiother Oncol. 2006 Oct;81(1):9-17. Epub 2006 Sep 28. Erratum in: Radiother Oncol. 2007 May;83(2):215. Mameghan, Heidi [corrected to Mameghan, Hedy].

PMID:
17011058
20.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM).

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206

Supplemental Content

Support Center